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Abstract: Importance The identification and understanding of the monogenic causes of neurodevelop-
mental disorders are of high importance for personalized treatment and genetic counseling. Objective
To identify and characterize novel genes for a specific neurodevelopmental disorder characterized by re-
fractory seizures, respiratory failure, brain abnormalities, and death in the neonatal period; describe the
outcome of glutaminase deficiency in humans; and understand the underlying pathological mechanisms.
Design, Setting, and Participants We performed exome sequencing of cases of neurodevelopmental dis-
orders without a clear genetic diagnosis, followed by genetic and bioinformatic evaluation of candidate
variants and genes. Establishing pathogenicity of the variants was achieved by measuring metabolites in
dried blood spots by a hydrophilic interaction liquid chromatography method coupled with tandem mass
spectrometry. The participants are 2 families with a total of 4 children who each had lethal, therapy-
refractory early neonatal seizures with status epilepticus and suppression bursts, respiratory insufficiency,
simplified gyral structures, diffuse volume loss of the brain, and cerebral edema. Data analysis occurred
from October 2017 to June 2018. Main Outcomes and Measures Early neonatal epileptic encephalopa-
thy with glutaminase deficiency and lethal outcome. Results A total of 4 infants from 2 unrelated
families, each of whom died less than 40 days after birth, were included. We identified a homozygous
frameshift variant p.(Asp232Glufs*2) in GLS in the first family, as well as compound heterozygous vari-
ants p.(Gln81*) and p.(Arg272Lys) in GLS in the second family. The GLS gene encodes glutaminase
(Enzyme Commission 3.5.1.2), which plays a major role in the conversion of glutamine into glutamate, the
main excitatory neurotransmitter of the central nervous system. All 3 variants probably lead to a loss of
function and thus glutaminase deficiency. Indeed, glutamine was increased in affected children (available
z scores, 3.2 and 11.7). We theorize that the potential reduction of glutamate and the excess of glutamine
were a probable cause of the described physiological and structural abnormalities of the central nervous
system. Conclusions and Relevance We identified a novel autosomal recessive neurometabolic disorder
of loss of function of glutaminase that leads to lethal early neonatal encephalopathy. This inborn error
of metabolism underlines the importance of GLS for appropriate glutamine homeostasis and respiratory
regulation, signal transduction, and survival.
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IMPORTANCE The identification and understanding of themonogenic causes of
neurodevelopmental disorders are of high importance for personalized treatment and
genetic counseling.
OBJECTIVE To identify and characterize novel genes for a specific neurodevelopmental
disorder characterized by refractory seizures, respiratory failure, brain abnormalities, and
death in the neonatal period; describe the outcome of glutaminase deficiency in humans;
and understand the underlying pathological mechanisms.
DESIGN, SETTING, AND PARTICIPANTS Weperformed exome sequencing of cases of
neurodevelopmental disorders without a clear genetic diagnosis, followed by genetic and
bioinformatic evaluation of candidate variants and genes. Establishing pathogenicity of the
variants was achieved bymeasuring metabolites in dried blood spots by a hydrophilic
interaction liquid chromatographymethod coupled with tandemmass spectrometry. The
participants are 2 families with a total of 4 children who each had lethal, therapy-refractory
early neonatal seizures with status epilepticus and suppression bursts, respiratory
insufficiency, simplified gyral structures, diffuse volume loss of the brain, and cerebral edema.
Data analysis occurred fromOctober 2017 to June 2018.
MAIN OUTCOMES ANDMEASURES Early neonatal epileptic encephalopathywith glutaminase
deficiency and lethal outcome.
RESULTS A total of 4 infants from 2 unrelated families, each of whom died less than 40 days
after birth, were included. We identified a homozygous frameshift variant p.(Asp232Glufs*2)
in GLS in the first family, as well as compound heterozygous variants p.(Gln81*) and
p.(Arg272Lys) in GLS in the second family. The GLS gene encodes glutaminase (Enzyme
Commission 3.5.1.2), which plays a major role in the conversion of glutamine into glutamate,
the main excitatory neurotransmitter of the central nervous system. All 3 variants probably
lead to a loss of function and thus glutaminase deficiency. Indeed, glutamine was increased in
affected children (available z scores, 3.2 and 11.7). We theorize that the potential reduction of
glutamate and the excess of glutamine were a probable cause of the described physiological
and structural abnormalities of the central nervous system.
CONCLUSIONS AND RELEVANCE We identified a novel autosomal recessive neurometabolic
disorder of loss of function of glutaminase that leads to lethal early neonatal encephalopathy.
This inborn error of metabolism underlines the importance of GLS for appropriate glutamine
homeostasis and respiratory regulation, signal transduction, and survival.
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E
pileptic encephalopathies are a large and heteroge-
neous group of disorders. Genetic factors are assumed
to be causative in most cases.1-4 In outbred popula-
tions, frequent causes of severe epileptic encephalopathy are
de novo heterozygous genetic variants.5-7 However, autoso-
mal recessive inheritance is common, especially for meta-
bolic disorders.8 Identification and characterization of ge-
netic causes of neurodevelopmental disorders is essential to
enable counselling of relatives regardingprognosis and recur-
rence risk. Understanding the pathologicalmechanisms is an
essential basic knowledge for developing and enabling per-
sonalized and specific treatment.
In this study, we describe pathogenic alterations in the
K-type mitochondrial glutaminase (GLS; Enzyme Commis-
sion 3.5.1.2) encoded by GLS that is ubiquitously expressed,
with a particularly high expression in the brain.9 Glutamin-
aseplaysapivotal role in theproductionofglutamate, themain
excitatoryneurotransmitter in the central nervous system, in-
cluding the brain stem respiratory center.10-12 In the respira-
tory center, respiratory volume, frequency, and rhythm are
regulated by information from chemoreceptors and mecha-
noreceptorsmediatedbyglutamatergic signal transduction.13
In addition, glutamate induces myelination of axons. It fur-
thermore fuels themitochondrial citric acid (tricarboxylic acid)
cycle throughα-ketoglutarate, thereby regulating energyme-
tabolism, which is important for the high energy demands of
the brain.14,15Glutamate is produced by GLS from glutamine,
an important ammonia detoxifier and a building block of pro-
teins, and a source of other amino acids, purines, and pyrimi-
dines.Here,wedescribe4 individuals from2 familieswithbi-
allelicGLS loss-of-functionvariants,who clinically presented
withneonatal respiratory failure, status epilepticuswith sup-
pression bursts, and early death.
Methods
Ethical Approval
All analyses were performed in concordance to the provi-
sions of the German Gene Diagnostic Act (Gendiagnostikge-
setz) and the General Data Protection Act (Bundesdaten-
schutzgesetz). The testingwas done as part of routine clinical
care. Theprojectwas approvedby the ethics committee of the
University of Leipzig, Germany in accordancewith theDecla-
ration of Helsinki.16 Written informed consent of all exam-
ined individuals or their legal representativeswasobtainedaf-
ter advice and information about the risks and benefits of the
study was given.
Exome Sequencing
We performed 2x100bp exome sequencing on a HiSeq4000
platform (Illumina) after library preparation with SureSe-
lectXT (AgilentGenomics) andenrichmentwithSureSelectAll
Human Version 6 (60Mb; Agilent Genomics). In one family,
we performed single-exome sequencing of 1 affected child
(coverage of ×10 at 98.7% of the targeted sequences). In the
other family,weperformed trio-exome sequencing; coverage
of ×10was achieved in 98.8%of targeted sequences in the af-
fected infant: 98.7% in 1 parent and 99.1% in the other par-
ent. Validation of the findings and segregation of the variants
were performedwith Sanger sequencing for all available fam-
ily members.
Variant Prioritization
Analysis of the raw data was performed using the software
Varfeed (LimbusMedical Technologies) and the variants were
annotated and prioritized using the software Varvis (Limbus
MedicalTechnologies).Toidentifypreviouslydescribedvariants,




ant attributes, and the published literature.
Blood Spot Analyses andMetabolic Measurements
Glutamine and glutamate concentrations were measured in
dried blood spots by a hydrophilic interaction liquid chroma-
tography method coupled with tandem mass spectrometry
(Xevo TQ; Waters). This method is based on a previously de-
scribedmethod for amino acid analysis in plasma,with slight
modifications.19
Statistical Analysis
To correct for spontaneous in vitro conversion of glutamine
intoglutamate,concentrationswereconvertedtozscoresbased
on 10control blood spots obtainedon the samedayand stored
under the same circumstances. z Scores greater than 2 were
considered significant. Data analysis occurred from October
2017 to June 2018.
Results
Family 1
One affected infant (Figure 1A) was a child of consanguine-
ous, healthy parents. The infant was born by cesarean sec-
tion. Apgar scores were 6, 5, and 7 at 1, 5, and 10minutes, re-
spectively, with limited spontaneous respiration andmarked
muscular hypotonia. The infant initially improvedwith short-
term ventilation via facemask and oxygen supplementation.
Key Points
Question What is the consequence of glutaminase deficiency?
Findings This study of 2 families with 4 affected children used
exome sequencing followed by functional analysis to show that
biallelic loss-of-function pathogenic variants in the glutaminase
gene GLS lead to early neonatal refractory seizures, respiratory
failure, structural brain abnormalities and cerebral edema, and
death within weeks after birth.
Meaning Based on these results, it is hypothesized that
glutaminase deficiency disturbs glutamine-glutamate homeostasis
and leads to neonatal lethal epileptic encephalopathy and
respiratory insufficiency; this emphasizes its importance for
respiratory regulation, neurotransmission, and survival.
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However, shortly after birth, respiration became insufficient.
In addition,myoclonic jerkswerenoted. The infantwas trans-
ferred to the neonatal intensive care unit and sedated, incu-
bated, and artificially ventilated. Within the next few hours,
focal seizures intensified and spread and eventually also in-
cluded tonic-clonic seizures of all limbs. The infant was car-
diorespiratory stable on the ventilator. Seizures were refrac-
tory to lorazepam, levetiracetam, sodium benzoate, valproic
acid, pulse steroid therapy, and a trial of dextromethorphan
given on suspicion of nonketotic hyperglycinemia. Tempo-
rary remissionof seizureswas achievedwhen startingpheno-
barbital and initiating a 3-day thiopental-induced coma.How-
ever, after discontinuation, seizures reoccurred within 1 day.
Similarly, a continuous infusion of ketamine was started and
led toa seizure-free intervalof2days, but thismedication then
lost its effect even after the dose was increased to 5mg/kg/h.
Physical examinations revealed an inadequate reaction to ex-
ternal stimuli, muscular hypotonia, absence of sucking re-
flex, and uncoordinatedmovements. Therewere no dysmor-
phic features.Resultsof themetabolicnewbornscreeningwere
unremarkable.Repeatedattempts towean the infant fromthe
ventilator were unsuccessful. Electroencephalography re-
vealed long-lasting suppressed activity that was interrupted
byshort, high-amplitudeΘactivity,meeting thecriteriaofper-
sistent burst-suppression patterns. Magnetic resonance
imaging (MRI) showed a simplified frontal gyral pattern with
an anterior-to-posterior gradient and deep and subcortical
white matter involvement (Figure 1A). A follow-up MRI later
showed gliosis, especially in the frontal deep white matter,
caused by brain parenchymal destruction, as well as marked
volumelossof the initiallynormal-appearingbasalganglia, cor-
pus callosum, thalami, brainstem, andvermis, all possibly be-
cause of direct destruction and secondary network injury
(Figure 1B-E).Onadiffusion-weightedmagnetic resonance im-
age, extensive vasogenic cerebral edemawas seen, especially
in the deepwhitematter and corpus callosum, whichwas in-
terpreted as being causedby the seizure activity. Therapywas
discontinued in agreement with the parents, and the infant
died. At that time, the diagnosis remained unknown.
Another infant of the family had died after a similar dis-
ease course.A summaryof thephenotype is given in theTable.
Family 2
Anaffected infant of this family (Figure 1B)was a child of non-
consanguineous, healthyparents. Pregnancyhadbeen largely
uneventful until the last month. During delivery at full term,
pethidine was administered, and meconium-stained amni-
otic fluid and a pathological cardiotocography were noticed.
Apgar scores were 2, 7, and 7 at 1, 5, and 10 minutes, respec-
tively,with limited spontaneous respiration andmarkedmus-
cular hypotonia. The infant improved with respiratory sup-
port. However, when respiratory support was withheld, the
infant exhibited Cheyne-Stokes respiration and was there-
fore transferred to the intensivecareunit.There, the infantwas
sedated, incubated, and artificially ventilated. Low arterial
bloodpressurewastreatedwithcatecholamine,dopamine,and
adrenaline.Additionally, diabetes insipiduswas suspectedbe-
cause of high diuresis, for which a trial of desmopressin was
administered. At day 2, the infant developed focal seizures,
withvariably combinedasymmetric tonicmovements, irregu-
lar eye movement, clonus of the eyelid and the upper and
the lower extremities, and myoclonic jerks. Electroencepha-
lography revealed long-lasting suppressed activity that was
Figure 1. Pedigrees of Families andMagnetic Resonance Images
of Affected Children
MRI of infant of family 1A MRI of infant of family 1B
Sagittal T2-weighted image of
infant of family 1
C Sagittal T2-weighted image of infant
of family 1
D
Trace map of diffusion-weighted
image of infant of family 1
E Axial T1-weighted image of infant
of family 2
F
A, Amagnetic resonance image (MRI) shows simplified gyral patterns and
destruction over time in axial T1 weighted image of the affected infant in family
1, including an anterior-to-posterior gradient and deep and subcortical white
matter involvement on day 1. B, Gliosis and volume loss of the basal ganglia and
thalami, as well as a pronounced white matter involvement. C and D, Sagittal
T2-weighted images shortly after birth and later, with reduction of an initially
normally constructed brainstem, vermis, and corpus callosum, with a prominent
cisterna magna also depicted. E, A trace map of a diffusion-weighted image
with a high signal at the splenium, pointing to vasogenic edema. F, An axial
T1-weighted image of an affected child of family 2, with a simplified gyral
pattern of the frontal lobes and white matter involvement of the corticospinal
tracts at the level of the posterior limb of the internal capsule.
Identification of a Loss-of-FunctionMutation in Neonatal Epileptic EncephalopathyWith Glutaminase Deficiency Original Investigation Research
jamaneurology.com (Reprinted) JAMANeurology Published online December 21, 2018 E3
© 2018 American Medical Association. All rights reserved.
Downloaded from jamanetwork.com by UZH Hauptbibliothek / Zentralbibliothek Zuerich user on 01/29/2019
Table. Genetic and Clinical Descriptions of Affected Offspring
Characteristic
Family 1 Family 2
1 2 1 2






Not tested c.695dup c.815G→A/c.241C→T c.815G→A/c.241C→T
Protein alteration Not tested p.(Asp232Glufs*2) p.(Arg272Lys)/p.(Gln81*) p.(Arg272Lys)/p.(Gln81*)
Zygosity Not tested Homozygous Compound heterozygous Compound heterozygous
Length at birth20
Length, cm Unknown 49 47 47
Percentile Unknown 25th 1st 1st
Weight at birth20
Weight, g Unknown 3040 2990 3000
Percentile Unknown 43rd 8th 11th
Head circumference at
birth20
Circumference, cm Unknown 36.5 Unknown 32
Percentile Unknown 90th Unknown 1st
Apgar scores
1 min Unknown 6 2 4
5 min Unknown 5 7 5
















Focal cerebral seizures within
10 min after birth
Focal seizures at day 2, followed by
variably combined asymmetric tonic
movements, irregular eye movement,
clonus of the eyelid and the upper and
the lower extremities, and single
myoclonic jerks
Myoclonic seizures of the
mouth at day 1
Response to therapy Similar to
affected sibling
Refractory Refractory Refractory
Muscular tonus Unknown Muscular hypotonia Muscular hypotonia Muscular hypotonia
Electroencephalographic
results
Unknown Burst-suppression patterns Burst-suppression patterns, ictal
pattern: variable focal onset and
variable morphologic features, often









Unknown 0 and 30 3 3
Results Unknown At birth, simplified frontal gyral
pattern with an anterior to
posterior gradient and deep and
subcortical white matter
involvement; on follow-up, gliosis,
volume loss of the initially normal
appearing basal ganglia, corpus
callosum, thalami, brain stem and
vermis, and vasogenic cerebral
edema
Simplified gyral pattern of the frontal
lobes and white matter involvement
Severe demyelination; calcium
spots and recess of the fibers in
the subcortical white matter
Dysmorphic features Unknown No No No














vigabatrin, vitamin B-6, and
phenytoin
Abbreviations: EEG, electroencephalogram; MRI, magnetic resonance imaging.
a NM_001256310.1
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interruptedby short, high-amplitudeΘactivity, a pattern con-
sistent with suppression bursts. Seizures were refractory to
phenobarbital, phenytoin, pyridoxine, midazolam, and topi-
ramate. A physical examination revealed muscular hypoto-
nia with absence of movements against gravity and absence
of reflexes. Therewerenodysmorphic features. AnMRIof the
brain revealed a simplified gyral pattern of the frontal lobes
and white matter involvement (Figure 1F), similar to that of
theother affected infants. Treatmentwas stopped, and the in-
fant died. The diagnosis remained unknown.
Another infant in the family showeda similar clinical pre-
sentation of neonatal respiratory failure and status epilepti-
cus with suppression bursts. On delivery, the infant had no
spontaneous respiration, and Apgar scores were 4, 5, and 7 at
1, 5, and 10 minutes. Respiratory support improved circula-
tion, but hypoventilation and apnea persisted.Within hours,
myoclonic seizures were notedwith a burst-suppression pat-
tern on electroencephalography, which failed to respond to
variousantiepilepticdrugs.AnMRIof thebrain revealedasim-
plified gyral pattern, particularly in the frontal lobes. The in-
fant died after treatment was discontinued. The Table pre-
sents a summary of the phenotype.
Genetic Results
Whole-exome sequencing (WES) revealed in 1 infant in fam-
ily 1ahomozygous frameshiftvariant inGLS (NM_001256310.1;
chr2:191765378, c.695dup, p.[Asp232Glufs*2]). Sanger se-
quencing confirmed the variant, and both parents are hetero-
zygous. There was no material available from the other af-
fected infant.
In family 2, trio WES revealed compound heterozygous
variants inGLS: NM_001256310.1; chr2:191746051, c.241C→T,
and p.(Gln81*) inherited from 1 parent and chr2:191766752,
c.815G→A, and p.(Arg272Lys) from the other parent. Sanger
sequencingconfirmedthevariants, andeachparentwas found
to be heterozygous for 1 of the variants. Also, we found that
3 of 4 healthy children in the family were heterozygous for
1 variant, while a fourth was homozygous for the wild type.
All 3 variants were absent from all publicly available da-
tabases, including GnomAD (last accessed March 8, 2018).21
The truncating variants probably lead to RNA nonsense-
mediated decay.22 In any case, translationwould not result in
a catalytically competent protein; Arg272 is conserved across
evolutionfromlampreys tovertebrates (Figure2A),and insilico
prediction tools like MutationTaster (MutationTaster prob-
ability value, 0.999 on a scale of 0 to 1), PolyPhen-2 (score,
0.995 on a scale of 0 to 1), and Combined Annotation Depen-
dent Depletion (raw Phil’s Read Editor [PHRED] score [Uni-
versity of Washington Genome Center], 34 on a scale of 1 to
40) suggest a pathogenic outcome of the variant.25-27 Avail-
able structural information28 suggests thatArg272plays a role
in stabilizationof theprotein fold andmay thereby reduce the
amount of active GLS (Figure 2B and Figure 2C).
Metabolic Assay
To confirm loss of function ofGLS as a consequence of the ge-
netic variants, amass spectrometry–basedmethodwasdevel-
oped to measure glutamine and glutamate in stored Guthrie
cards from the newborn period of all of the children of family
2, parallel to segregation analyses. Spontaneous in vitro con-
version of glutamine into glutamate during storage was ob-
served and corrected by comparing with control blood spots
obtained on the same day and stored under the same condi-
tions. Glutamine levelswere significantly increased in the af-
fected individuals (z scores = 3.2 and 11.7) compared with
healthy control neonates (z scores of siblings in family 2: 0.5,
0.4, 2.0, and0.2), underliningGLS loss of function (Figure 2D
andFigure 2E).Notably, glutaminewasborderline elevated in
1 sibling in family 2 (z = 2.0), but not in the other siblings, in-
cluding a sibling sharing the same genotype. Glutamate lev-
els, which remained relatively stable during storage, did not
differ between the affected individuals and control partici-
pants (z scores = 0.7 and −0.8; Figure 2F and Figure 2G);
z scores of siblings in family 2were −0.7, −0.5, −1.9, and −0.6.
Discussion
We describe 4 children in 2 unrelated families with overlap-
ping phenotypes of lethal neonatal-onset respiratory failure
and refractory suppression-burst epileptic encephalopathy.
While therewerenoobviousmalformationsororganic anoma-
lies, brain MRIs within days of birth showed a simplified gy-
ral patternwithananterior-to-posterior gradient anddeepand
subcortical white matter involvement. Genetic analyses re-
vealed a homozygous truncating variant ofGLS in family 1; in
family2, therewere2compoundheterozygousvariants, a trun-
catingandamissensevariant, inGLS.Molecularmodeling sug-
gests that themissense variant influencesGLS enzyme stabil-
ity and results in a loss of function. In support of this concept,
metabolicanalysisondriedbloodspotsobtainedfromthenew-
born screening revealed increasedglutamine levels inboth af-
fected children of family 2. The increase of glutamine levels
in ahealthy siblingwasborderline (z score = 2) and thusmuch
less than 2 affected siblings (z scores = 11.7 and 3.2, respec-
tively). This mild elevation of glutamine may be because of
technical artifacts or to a minor influence of the mutation on
the biochemical values but not on the clinical presentation.
Similar phenomena are observed in other metabolic disor-
ders, such as phenylketonuria.29
The highly overlapping phenotype of the affected chil-
dren in both families, as well as the comparable genetic find-
ings, implicate a biallelic loss-of-function variants inGLS that
leads to a novel metabolic disorder of early neonatal, refrac-
tory, and lethal epileptic encephalopathy.
The GLS loss of function seems to have profound conse-
quences forbothconstructionandmaintenanceofbrain struc-
tures. Although the glutamate levels in the dried blood spots
were normal, this does not exclude decreased glutamate lev-
els in thebrain, ashasbeenshowninknockoutmousemodel.30
The GLS gene is highly expressed in the brain and has a piv-
otal role in creating glutamate abundance in the brain, con-
trary to thesystemiccirculation, inwhichglutamine is themost
abundant amino acid.31,32
BrainMRIsof theaffectedchildrenofboth families showed
simplified gyral patterns. An affected child of family 1was fol-
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lowed up after 1 month, revealing cerebral vasogenic edema
anddestructionof initiallynormalappearingbasalganglia, cor-
pus callosum, thalami, brain stemandvermis.Cerebral edema
might be because of glutamine accumulation, which is asso-
ciated with cerebral osmotic, thus cellular edema.33,34 How-
ever, the observed vasogenic (rather than cellular) edema in
thewhitematter is also a known consequence of ongoing epi-
leptic activity.35Subsequentdamageof thewhitematter tracts
results in gliosis formation, which was seen in this infant in
the follow-up MRI.36
Figure 2. Molecular Modeling ofMissense Variant inGLS and Glutamine and Glutamate Analyses
in Guthrie Cards of Family 2
A AAA
Conservation of Arg272 per multiple sequence alignmentA


















































































































































A, Multiple sequence alignment
reveals conservation of Arg272
(marked red) throughout evolution
across several species (https:
//genome.ucsc.edu; human hg19
[Genome Reference Consortium
human build 37]). B, Structure of
GLS, including the N-terminal loop
(gray), based on pdb entry 3ss3.
C, Glutamate (green) taken from pdb
entry 3ss5 to indicate the location of
the active site, with Arg272 and
Glu374 shown and a detailed view of
the environment of Arg272. The
backbone amid Arg272 is engaged in
a hydrogen bond with Gly167 and
oriented parallel to the side chain of
Arg169, both localized in the
N-terminal lobe with water. Parts B
and Cwere generated with moscript
and raster 3D.23,24 Concentration of
glutamine (D) and glutamate (E) in
Guthrie cards and z scores of
glutamine (F) and glutamate (G) in
Guthrie cards of the children of family
2 (black squares), calculated from the
mean and standard deviation of 10
control participants for each
measurement obtained at the same
day and stored under the same
conditions (white dots) and
expressed as z scores.
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Decreased glutamate levels may also contribute to the
pathogenic brain morphology. As glutamate induces myelin
synthesis, decreased glutamate levels are likely to result in
whitematter involvement, probably explaining theunmyelin-
ated corticospinal tract at the level of the thalami seen in the
affected children.37
Thenormal glutamate levels in dried blood spotsmight be
explained byuptake from thediet and thenumerous enzymes
that metabolize glutamate.36 These enzymes might have cor-
rected theglutamatedeficiencycreatedbyGLS lossof function,
pointing to the importance ofmaintained glutamate levels.
TheGLS lossof functionhas severe consequencesonbrain
physiology. Glutamate facilitates signal transduction in the
brainstem respiratory center, where respiratory volume, fre-
quency, and rhythm are regulated immediately after birth.13
Respiratory dysfunction in the affected children is therefore
likely a consequence ofGLS loss of function. AGLS knockout
mouse model supports this observation, because these mice
also develop respiratory dysfunction.30 This mouse model
shows that GLS deficiency leads to reduced neuronal gluta-
mate release, reducedchemosensitivity to carbondioxide, hy-
poventilation, andadecreased tidalvolume.This is in linewith
the respiratory phenotype of the affected children, which is
characterized by hypoventilation, apnea, and Cheyne-Stokes
respiration. It cannot be fully excluded that respiratory dys-
function is secondary to epilepsy. However, in the knockout
mousemodel, respiratory dysfunctionwas observed, and the
authors did not report seizures.30
The observed refractory epilepsy of the affected children
maybetheconsequenceofglutamatedeficiencycausedbyGLS
loss of function. Disturbed glutamine-glutamate shuttling is
a knowncauseof epilepsy.38,39Another knownmechanismof
epilepsy ismitochondrial dysfunctionvia energydepletion.40
Glutamate deficiency likely leads to a decreased tricarboxylic
acidcycle fluxbecause there is lessα-ketoglutarate supply, and
it might therefore lead to mitochondrial dysfunction. Inter-
estingly, another inborn error of glutamate metabolism with
mitochondrial dysfunction has been associated with neona-
tal epileptic encephalopathy and suppressionbursts. This de-
fect is caused by biallelic variants inmitochondrial glutamate
carrier 1 (GC1, encoded by SLC25A22), which lead to reduced
mitochondrial glutamate transport and oxidation.41,42
Interestingly, patients with different defects in the gluta-
mate-metabolizing pathway show clinical parallels and dif-
ferences. Patients with a SLC25A22 defect present similarly
with very early neonatal severe intractable myoclonic sei-
zures,muscularhypotonia, andepileptic encephalopathy.41,42
There is no knowneffective treatment, and childrenwith this
condition either die within 1 to 2 years after birth or survive
in a persistent vegetative state. Deficiency of glutamine syn-
thetase (Enzyme Commission 6.3.1.2), which performs the
reverse reactionofGLS, has been reported in 3 individuals. As
expected, these patients presented biochemically with de-
creased glutamine concentrations, rather than increased
concentrations, in thebrain, plasma, andurine.39,43Addition-
ally, they exhibited hyperammonemia, which was absent
in our patients. Nevertheless, despite the contrasting bio-
chemical phenotype, these patients also exhibited neonatal
encephalopathy, seizures, respiratory failure, andearlydeath.
However, glutamine synthetase–deficient individuals did
not show suppression bursts on electroencephalographic
examination.
Interestingly, in all described disorders affecting gluta-
mate metabolism, disturbed glutamate homeostasis leads to
a severeneurological phenotype.Underphysiological circum-
stances, homeostasis of glutamine andglutamate in the brain
is strictly regulated by the glutamine-glutamate shuttle. Glu-
tamate is excreted byneurons into the synaptic cleft as a neu-
rotransmitter and absorbed by astrocytes, where it is con-
verted into glutamine by glutamine synthetase. Glutamine is
then transported towardneuronsandagainconverted intoglu-
tamate by glutaminase to restart signal transduction.38,44 It is
therefore not surprising that disturbed glutamate homeosta-
sis, either by defective synthesis in both directions or by de-
fective transport, is detrimental for neurological functioning.
This inborn error of metabolism underlines the impor-
tance ofGLS for appropriate glutamine-glutamate homeosta-
sis and respiratory regulation, neurotransmission, and sur-
vival. It is quitepossible thatdifferentvariants inGLSmay lead
to milder phenotypes (eg, ones caused by hypomorphic mu-
tations). Independent reporting of additional affected indi-
vidualswoulddelineate thephenotypeand its correlationwith
the genotype.
Limitations
This study describes the findings of 2 families and 4 affected
individuals. Further cases are necessary to further delineate
the phenotype and describe its full spectrum. The functional
analyses in this studywere limited to dry blood spots. Analy-
ses in cell lines may lead to deviating findings and are neces-
sary to better understand the pathological mechanisms and
suggest therapeutic approaches.
Conclusions
In conclusion,we describe a novel autosomal recessive cause
of lethal neonatal-onset respiratory failure and epileptic en-
cephalopathy caused by biallelic loss-of-function variants in
GLS.We describe a novel autosomal recessive disorder of le-
thal neonatal-onset respiratory failure andepileptic encepha-
lopathy caused by biallelic loss-of-function variants in GLS.
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